Holding company focused on investments in real estate and pharmaceuticals.
Rafael Holdings, Inc. is a diversified company with interests spanning clinical and early stage pharmaceutical ventures, as well as commercial real estate assets across the United States and Israel. Operating through two primary segments, Healthcare and Real Estate, the company is actively involved in advancing therapies that target metabolic disparities between normal cells and cancer cells.
In the Healthcare segment, Rafael Holdings focuses on the development and commercialization of innovative treatments. Notably, its flagship drug candidate, CPI-613 (devimistat), is currently undergoing Phase III clinical trials. This drug is being evaluated for its potential efficacy in treating metastatic pancreatic cancer and acute myeloid leukemia, reflecting the company's commitment to addressing critical medical needs.
Meanwhile, in the Real Estate segment, Rafael Holdings manages a portfolio of commercial properties strategically located in key markets in the United States and Israel. These assets provide a stable foundation for the company's operations and contribute to its overall financial resilience and growth strategy.
Founded in 2017 and headquartered in Newark, New Jersey, Rafael Holdings leverages its dual focus on healthcare innovation and real estate investment to drive sustainable value creation. The company's strategic approach underscores its dedication to advancing medical science while concurrently optimizing its real estate holdings to support long-term financial objectives.